Merck: gets positive trial results for diabetes drug Januvia
(CercleFinance.com) - Merck presented new data from a study showing that Januvia resulted in greater blood glucose reduction and more patients reaching glycated hemoglobin (A1C) goal, compared to those who discontinued Januvia alone.
In another study, amongst patients with mild renal impairment inadequately controlled, treatment with Januvia showed non-inferiority and superiority in reducing A1C levels compared with Novo Nordisk's dapagliflozin.
These results were presented over the weekend at the scientific sessions of the American Diabetes Association (ADA) in Orlando, Florida.
Januvia is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In another study, amongst patients with mild renal impairment inadequately controlled, treatment with Januvia showed non-inferiority and superiority in reducing A1C levels compared with Novo Nordisk's dapagliflozin.
These results were presented over the weekend at the scientific sessions of the American Diabetes Association (ADA) in Orlando, Florida.
Januvia is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type-2 diabetes mellitus.
Copyright (c) 2018 CercleFinance.com. All rights reserved.